AVAT-031

AVAT-031 is an investigational solid dose pharmaceutical drug being developed by Avata Biosciences. It is part of a pipeline of next-generation cannabinoid medicines, utilizing synthetic cannabinoids and novel formulation processes. The primary focus for AVAT-031 appears to be neurological diseases, with specific indications in development including adult focal epilepsy, pediatric focal epilepsy, schizophrenia, opioid sparing (pain management), and addiction. The precise mechanism of action has not been disclosed publicly but is likely related to modulation of the endocannabinoid system given the company's focus on synthetic cannabinoids[1].